+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

SAXENDA (Liraglutide), Drug Insight and Market Forecast - 2032

  • PDF Icon

    Report

  • 30 Pages
  • September 2022
  • Region: Global
  • DelveInsight
  • ID: 5659580
“SAXENDA (Liraglutide), Drug Insight and Market Forecast - 2032” report provides comprehensive insights about SAXENDA (Liraglutide) for Obesity in the 7MM. A detailed picture of the SAXENDA (Liraglutide) for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the SAXENDA (Liraglutide) for Obesity. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAXENDA (Liraglutide) market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.

Drug Summary

SAXENDA (Liraglutide) is a Glucagon-like Peptide 1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia) and pediatric patients aged 12 years and older with a body weight above 60 kg, and an initial BMI corresponding to 30 kg/m2 for adults (obese) by international cut-off.

SAXENDA is recommended at a dose of 3 mg per day. It is recommended to start with 0.6 mg per day for one week. The dose should be increased at weekly intervals until a dose of 3 mg is reached. If pediatric patients are unable to tolerate an increased dose during dose escalation, the dose may be reduced to the previous level. Pediatric patients may require dose escalation for up to 8 weeks. Pediatric patients who are unable to tolerate 3 mg per day may have their dose reduced to 2.4 mg per day.

Liraglutide is an acylated human Glucagon-like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs. Endogenous GLP-1 has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, Dipeptidyl Peptidase 4 (DPP-4) and Neutral Endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of thirteen hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once-daily administration, is a result of self-association that delays absorption, plasma protein binding, and stability against metabolic degradation by DPP-4 and NEP.

GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. In animal studies, peripheral administration of liraglutide resulted in the presence of liraglutide in specific brain regions regulating appetite, including the hypothalamus. Although liraglutide activated neurons in brain regions known to regulate appetite, specific brain regions mediating the effects of liraglutide on appetite were not identified in rats.

Scope of the Report

The report provides insights into:

  • A comprehensive product overview including the SAXENDA (Liraglutide) description, mechanism of action, dosage and administration, research and development activities in Obesity.
  • Elaborated details on SAXENDA (Liraglutide) regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the SAXENDA (Liraglutide) research and development activity in Obesity in detail across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around SAXENDA (Liraglutide).
  • The report contains forecasted sales of SAXENDA (Liraglutide) for Obesity till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for Obesity.
  • The report also features the SWOT analysis with analyst views for SAXENDA (Liraglutide) in Obesity.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SAXENDA (Liraglutide) Analytical Perspective

In-depth SAXENDA (Liraglutide) Market Assessment

This report provides a detailed market assessment of SAXENDA (Liraglutide) in Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

SAXENDA (Liraglutide) Clinical Assessment

The report provides the clinical trials information of SAXENDA (Liraglutide) in Obesity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Obesity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SAXENDA (Liraglutide) dominance.
  • Other emerging products for Obesity are expected to give tough market competition to SAXENDA (Liraglutide) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SAXENDA (Liraglutide) in Obesity.
  • The in-depth analysis of the forecasted sales data of SAXENDA (Liraglutide) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAXENDA (Liraglutide) in Obesity.

Key Questions Answered

  • What is the product type, route of administration and mechanism of action of SAXENDA (Liraglutide)?
  • What is the clinical trial status of the study related to SAXENDA (Liraglutide) in Obesity and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAXENDA (Liraglutide) development?
  • What are the key designations that have been granted to SAXENDA (Liraglutide) for Obesity?
  • What is the forecasted market scenario of SAXENDA (Liraglutide) for Obesity?
  • What are the forecasted sales of SAXENDA (Liraglutide) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available in Obesity and how are they giving competition to SAXENDA (Liraglutide) for Obesity?
  • Which are the late-stage emerging therapies under development for the treatment of Obesity?


This product will be delivered within 2 business days.

Table of Contents

1. Report Introduction
2. SAXENDA (Liraglutide) Overview
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical Studies
2.2.2. Clinical Trials Information
2.2.3. Safety and Efficacy
2.3. Regulatory Milestones
2.4. Other Developmental Activities
2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)4. Competitive Landscape (Late-stage Emerging Therapies) *
5. SAXENDA (Liraglutide) Market Assessment
5.1. Market Outlook of SAXENDA (Liraglutide) in Obesity
5.2. 7MM Market Analysis
5.2.1. Market Size of SAXENDA (Liraglutide) in the 7MM for Obesity
5.3. Country-wise Market Analysis
5.3.1. Market Size of SAXENDA (Liraglutide) in the United States for Obesity
5.3.2. Market Size of SAXENDA (Liraglutide) in Germany for Obesity
5.3.3. Market Size of SAXENDA (Liraglutide) in France for Obesity
5.3.4. Market Size of SAXENDA (Liraglutide) in Italy for Obesity
5.3.5. Market Size of SAXENDA (Liraglutide) in Spain for Obesity
5.3.6. Market Size of SAXENDA (Liraglutide) in the United Kingdom for Obesity
5.3.7. Market Size of SAXENDA (Liraglutide) in Japan for Obesity
6. SWOT Analysis7. Analysts’ Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. Publisher Capabilities10. Disclaimer11. About the Publisher12. Report Purchase Options
List of Tables
Table 1: SAXENDA (Liraglutide), Clinical Trial Description, 2022
Table 2: SAXENDA (Liraglutide) : General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: SAXENDA (Liraglutide) Market Size in the 7MM, in USD million (2019-2032)
Table 6: SAXENDA (Liraglutide) Market Size in the US, in USD million (2019-2032)
Table 7: SAXENDA (Liraglutide) Market Size in Germany, in USD million (2019-2032)
Table 8: SAXENDA (Liraglutide) Market Size in France, in USD million (2019-2032)
Table 9: SAXENDA (Liraglutide) Market Size in Italy, in USD million (2019-2032)
Table 10: SAXENDA (Liraglutide) Market Size in Spain, in USD million (2019-2032)
Table 11: SAXENDA (Liraglutide) Market Size in the UK, in USD million (2019-2032)
Table 12: SAXENDA (Liraglutide) Market Size in Japan, in USD million (2019-2032)
List of Figures
Figure 1: Changes in Weight at Week 56 for Studies 1, 2, and 3
Figure 2: Changes in Weight at Week 56 and Week 160 for study 1 (Subset of Patients With Abnormal Blood Glucose at Randomization)
Figure 3: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 1 (Patient Without Diabetes)
Figure 4: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 2 (Patient With Diabetes Mellitus)
Figure 5: The Time Course of Change in BMI SDS With Saxenda and Placebo From Baseline Through Week 56
Figure 6: Changes in Weight and BMI at Week 56 for Study 4 (Pediatric Patients Ages 12 to Less Than 18)
Figure 7: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 4 (Pediatric Patients Ages 12 to Less Than 18)
Figure 8: SAXENDA (Liraglutide) Market Size in the 7MM, USD million (2019-2032)
Figure 9: SAXENDA (Liraglutide) Market Size in the United States, USD million (2019-2032)
Figure 10: SAXENDA (Liraglutide) Market Size in Germany, USD million (2019-2032)
Figure 11: SAXENDA (Liraglutide) Market Size in France, USD million (2019-2032)
Figure 12: SAXENDA (Liraglutide) Market Size in Italy, USD million (2019-2032)
Figure 13: SAXENDA (Liraglutide) Market Size in Spain, USD million (2019-2032)
Figure 14: SAXENDA (Liraglutide) Market Size in the United Kingdom, USD million (2019-2032)
Figure 15: SAXENDA (Liraglutide) Market Size in Japan, USD million (2019-2032)